Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3532)
All Articles published online
|
Jan 7, 2008 (publication date) through Apr 18, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Koelewijn CL, Schwartz MP, Samsom M, Oldenburg B. C-reactive protein levels during a relapse of Crohn’s disease are associated with the clinical course of the disease. World J Gastroenterol 2008; 14(1): 85-89 [PMID: 18176967 DOI: 10.3748/wjg.14.85] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v14/i1/85.htm |
| Number | Citing Articles |
| 1 |
Dan Turner, David R. Mack, Jeffrey Hyams, Neal LeLeiko, Anthony Otley, James Markowitz, Yair Kasirer, Aleixo Muise, Cynthia H. Seow, Mark S. Silverberg, Wallace Crandall, Anne M. Griffiths. C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis. Journal of Crohn's and Colitis 2011; 5(5): 423 doi: 10.1016/j.crohns.2011.05.003
|
| 2 |
Sadik Saman, Martin Goetz, Judith Wendler, Nisar P. Malek, Jan Wehkamp, Thomas Klag. Ustekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria. Intestinal Research 2019; 17(3): 340 doi: 10.5217/ir.2019.00012
|
| 3 |
Marisa Iborra, Belén Beltrán, Pilar Nos. Noninvasive Testing for Mucosal Inflammation in Inflammatory Bowel Disease. Gastrointestinal Endoscopy Clinics of North America 2016; 26(4): 641 doi: 10.1016/j.giec.2016.06.005
|
| 4 |
Ryota Iwasa, Akihiro Yamada, Koji Sono, Ryuichi Furukawa, Ken Takeuchi, Yasuo Suzuki. C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study. BMC Gastroenterology 2015; 15(1) doi: 10.1186/s12876-015-0333-z
|
| 5 |
Jee Hye Kwon, Jong Pil Im, Byong Duk Ye, Jae Hee Cheon, Hyun Joo Jang, Kang Moon Lee, You Sun Kim, Sang Wook Kim, Young Ho Kim, Geun Am Song, Dong Soo Han, Won Ho Kim, Joo Sung Kim. Disease Phenotype, Activity and Clinical Course Prediction Based on C-Reactive Protein Levels at Diagnosis in Patients with Crohn’s Disease: Results from the CONNECT Study. Gut and Liver 2016; 10(4): 595 doi: 10.5009/gnl15411
|
| 6 |
Reena Khanna, Brian G. Feagan. Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune‐Mediated Inflammatory Diseases. 2019; : 25 doi: 10.1002/9781119289234.ch2
|
| 7 |
Maria H. Lönnkvist, Elvar Theodorsson, Mikael Holst, Tryggve Ljung, Per M. Hellström. Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy. Scandinavian Journal of Gastroenterology 2011; 46(4): 420 doi: 10.3109/00365521.2010.539253
|
| 8 |
Shannon Chang, Lisa Malter, David Hudesman. Disease monitoring in inflammatory bowel disease. World Journal of Gastroenterology 2015; 21(40): 11246-11259 doi: 10.3748/wjg.v21.i40.11246
|
| 9 |
Helena Edlund, Ana-Marija Grisic, Casper Steenholdt, Mark A. Ainsworth, Jørn Brynskov, Wilhelm Huisinga, Charlotte Kloft. Absence of Relationship Between Crohn's Disease Activity Index or C-Reactive Protein and Infliximab Exposure Calls for Objective Crohn's Disease Activity Measures for the Evaluation of Treatment Effects at Treatment Failure. Therapeutic Drug Monitoring 2019; 41(2): 235 doi: 10.1097/FTD.0000000000000590
|
| 10 |
Mahmoud Mosli, Asala Saeedi, Majed Alnefaie, Noor Bawahab, Lujain Abdo, Seigha Shobai, Majid Alsahafi, Omar Saadah. Awareness and cognition of illness in Saudi Arabian patients with Crohn's disease. Saudi Journal of Gastroenterology 2021; 27(2): 91 doi: 10.4103/sjg.SJG_371_20
|
| 11 |
Ivy K.M. Law, Michelle W. Cheng, David Q. Shih, Dermot P.B. McGovern, Hon Wai Koon. Antimicrobial Peptides in Gastrointestinal Diseases. 2018; : 35 doi: 10.1016/B978-0-12-814319-3.00003-9
|
| 12 |
Sayan Malakar. Clinical Significance of C-reactive Protein. 2020; : 59 doi: 10.1007/978-981-15-6787-2_3
|
| 13 |
Alice Freitas da Silva, Maria Eliana Madalozzo Schieferdecker, Cláudia Seely Rocco, Heda Maria Barska dos Santos Amarante. Relação entre estado nutricional e atividade inflamatória em pacientes com doença inflamatória intestinal. ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) 2010; 23(3): 154 doi: 10.1590/S0102-67202010000300005
|
| 14 |
Bincy P. Abraham, Selvi Thirumurthi. Clinical significance of inflammatory markers. Current Gastroenterology Reports 2009; 11(5): 360 doi: 10.1007/s11894-009-0055-x
|
| 15 |
E Iaculli, M Agostini, L Biancone, C Fiorani, A Di Vizia, F Montagnese, S Sibio, A Manzelli, M Tesauro, A Rufini, GS Sica. C-reactive protein levels in the perioperative period as a predictive marker of endoscopic recurrence after ileo-colonic resection for Crohn’s disease. Cell Death Discovery 2016; 2(1) doi: 10.1038/cddiscovery.2016.32
|
| 16 |
W. Kruis, A. Katalinic, T. Klugmann, G.-R. Franke, J. Weismüller, L. Leifeld, S. Ceplis-Kastner, B. Reimers, B. Bokemeyer. Predictive factors for an uncomplicated long-term course of Crohn's disease: A retrospective analysis. Journal of Crohn's and Colitis 2013; 7(7): e263 doi: 10.1016/j.crohns.2012.10.012
|
| 17 |
Jose-Manuel Benitez, Marie-Alice Meuwis, Catherine Reenaers, Catherine Van Kemseke, Paul Meunier, Edouard Louis. Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring. Gut 2013; 62(12): 1806 doi: 10.1136/gutjnl-2012-303957
|
| 18 |
Laurent Peyrin-Biroulet, Julián Panés, William J. Sandborn, Séverine Vermeire, Silvio Danese, Brian G. Feagan, Jean-Frédéric Colombel, Stephen B. Hanauer, Beth Rycroft. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clinical Gastroenterology and Hepatology 2016; 14(3): 348 doi: 10.1016/j.cgh.2015.06.001
|
| 19 |
Gary P Toedter, Marion Blank, Yinghua Lang, Dion Chen, William J Sandborn, Willem J S de Villiers. Relationship of C-Reactive Protein With Clinical Response After Therapy With Ustekinumab in Crohn's Disease. The American Journal of Gastroenterology 2009; 104(11): 2768 doi: 10.1038/ajg.2009.454
|
| 20 |
Min Seob Kwak, Kyung-Jo Kim, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang. Elevated C-reactive protein is associated with disease progression in patients with mild Crohn’s disease. SpringerPlus 2016; 5(1) doi: 10.1186/s40064-016-2606-6
|
| 21 |
Guillaume Bouguen, Barrett G. Levesque, Brian G. Feagan, Arthur Kavanaugh, Laurent Peyrin–Biroulet, Jean–Frederic Colombel, Stephen B. Hanauer, William J. Sandborn. Treat to Target: A Proposed New Paradigm for the Management of Crohn's Disease. Clinical Gastroenterology and Hepatology 2015; 13(6): 1042 doi: 10.1016/j.cgh.2013.09.006
|
| 22 |
Christofi Theodoulakis, Yiorgos Apidianakis. Life Extension. Healthy Ageing and Longevity 2015; 3: 151 doi: 10.1007/978-3-319-18326-8_7
|
| 23 |
Giulia Roda, Alessandra Caponi, Marco Benevento, Paolo Nanni, Laura Mezzanotte, Andrea Belluzzi, Lloyd Mayer, Aldo Roda. New proteomic approaches for biomarker discovery in inflammatory bowel disease. Inflammatory Bowel Diseases 2010; 16(7): 1239 doi: 10.1002/ibd.21212
|
| 24 |
Yibin Zhu, Haili Xu, Wei Liu, Weilin Qi, Xiaoyan Yang, Lingna Ye, Qian Cao, Wei Zhou. Glasgow prognostic score is a practical predictive index for postoperative intra-abdominal septic complications after bowel resection in Crohn’s disease patients. International Journal of Colorectal Disease 2018; 33(7): 947 doi: 10.1007/s00384-018-3035-5
|
| 25 |
Glen Doherty, Konstantinos H Katsanos, Johan Burisch, Matthieu Allez, Konstantinos Papamichael, Andreas Stallmach, Ren Mao, Ingrid Prytz Berset, Javier P Gisbert, Shaji Sebastian, Jarosław Kierkuś, Loris Lopetuso, Edyta Szymanska, Edouard Louis. European Crohn’s and Colitis Organisation Topical Review on Treatment Withdrawal [‘Exit Strategies’] in Inflammatory Bowel Disease. Journal of Crohn's and Colitis 2018; 12(1): 17 doi: 10.1093/ecco-jcc/jjx101
|
| 26 |
Dania Alrefai, Jennifer Jones, Wael El-Matary, Susan Whiting, Abdulrahman Aljebreen, Naghmeh Mirhosseini, Hassan Vatanparast. The Association of Vitamin D Status with Disease Activity in a Cohort of Crohn’s Disease Patients in Canada. Nutrients 2017; 9(10): 1112 doi: 10.3390/nu9101112
|
| 27 |
Pavol Papay, Ana Ignjatovic, Konstantinos Karmiris, Heda Amarante, Pal Miheller, Brian Feagan, Geert D'Haens, Philippe Marteau, Walter Reinisch, Andreas Sturm, Flavio Steinwurz, Laurence Egan, Julián Panés, Edouard Louis, Jean-Frédéric Colombel, Remo Panaccione. Optimising monitoring in the management of Crohn's disease: A physician's perspective. Journal of Crohn's and Colitis 2013; 7(8): 653 doi: 10.1016/j.crohns.2013.02.005
|
| 28 |
Amanda M. Lynn, Edward V. Loftus. Biomarkers in Inflammatory Bowel Diseases. 2019; : 57 doi: 10.1007/978-3-030-11446-6_6
|
| 29 |
Fernando Magro, Eduardo Rodrigues-Pinto, João Santos-Antunes, Filipe Vilas-Boas, Susana Lopes, Amadeu Nunes, Claudia Camila-Dias, Guilherme Macedo. High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment. Journal of Crohn's and Colitis 2014; 8(2): 129 doi: 10.1016/j.crohns.2013.07.005
|
| 30 |
Fernando Magro, Paula Sousa, Paula Ministro. C-reactive protein in Crohn’s disease: how informative is it?. Expert Review of Gastroenterology & Hepatology 2014; 8(4): 393 doi: 10.1586/17474124.2014.893821
|
| 31 |
Min Seob Kwak, Duk Hwan Kim, Soo Jung Park, Tae Il Kim, Sung Pil Hong, Won Ho Kim, Jae Hee Cheon. Efficacy of early immunomodulator therapy on the outcomes of Crohn’s disease. BMC Gastroenterology 2014; 14(1) doi: 10.1186/1471-230X-14-85
|
| 32 |
ANNA-ISABELLE KÄLSCH, ELENA CSERNOK, DOMINIK MÜNCH, RAINER BIRCK, BENITO A. YARD, WOLFGANG GROSS, THORSTEN KÄLSCH, WILHELM H. SCHMITT. Use of Highly Sensitive C-Reactive Protein for Followup of Wegener’s Granulomatosis. The Journal of Rheumatology 2010; 37(11): 2319 doi: 10.3899/jrheum.100302
|
| 33 |
R. Queiro, D. Ginard. Ustekinumab en la artritis psoriásica y la enfermedad de Crohn. Actas Dermo-Sifiliográficas 2012; 103: 65 doi: 10.1016/S0001-7310(12)70011-X
|
| 34 |
Xue Guo, Chen Huang, Jing Xu, Haoming Xu, Le Liu, Hailan Zhao, Jiaqi Wang, Wenqi Huang, Wu Peng, Ye Chen, Yuqiang Nie, Yongjian Zhou, Youlian Zhou. Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease. Frontiers in Nutrition 2022; 8 doi: 10.3389/fnut.2021.818902
|
| 35 |
Jason Orlando Dimitri Musci, Jack Stephen Cornish, Jan Däbritz. Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases. Journal of Gastroenterology 2016; 51(6): 531 doi: 10.1007/s00535-016-1191-3
|
| 36 |
Reena Khanna, Neeraj Narula, Brian G Feagan. The Role of Biomarkers in Clinical Trials of Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018; 24(8): 1619 doi: 10.1093/ibd/izy195
|
| 37 |
Maria E. Moscandrew, Edward V. Loftus. Diagnostic advances in inflammatory bowel disease (imaging and laboratory). Current Gastroenterology Reports 2009; 11(6): 488 doi: 10.1007/s11894-009-0074-7
|